Top news of TCT 2021: CABG vs. FFR-guided PCI, LAA closure devices and more

Healio and Cardiology Today have curated a list of the most-read headlines from TCT 2021.

Readers were most interested in the results of the SWISS-APERO trial of two left atrial appendage closure devices; the use of fractional flow reserve-guided PCI compared with surgery for three-vessel CAD; short- vs. long-term dual antiplatelet therapy following PCI; and more.

Head-to-head trial of LAA closure devices yields mixed results: SWISS-APERO

In a head-to-head trial of the Amplatzer Amulet and Watchman FLX LAA closure devices, the primary endpoint of crossover to the other device or residual LAA patency at 45 days was similar, researchers reported. Read more

FFR-guided PCI for three-vessel CAD not noninferior to surgery at 1 year: FAME 3

In the FAME 3 trial, PCI guided by FFR failed to meet noninferiority for reduction of MACCE at 1 year compared with CABG in patients with three-vessel CAD. Read more

Abbreviated DAPT beneficial after PCI in high-risk patients regardless of MI status

In a subgroup analysis of MASTER-DAPT, regardless of whether patients had a history of MI, 1-month DAPT after PCI was noninferior to 3-month or longer DAPT for ischemic events and conferred a reduction in bleeding events. Read more

TAVR cost-saving vs. surgery in low-risk patients at 2 years

In an economic analysis from the PARTNER 3 trial, transcatheter aortic valve replacement was economically dominant compared with surgery at 2 years in patients with severe aortic stenosis at low surgical risk. Read more

LAA closure remains noninferior to direct oral anticoagulants over long term

Among patients with atrial fibrillation at high risk for stroke, left atrial appendage closure remained noninferior to direct oral anticoagulation for preventing major CV and neurological events out to 4 years. Read more

Post-PCI, clopidogrel monotherapy after 1 month reduces bleeding risk vs. 12-month DAPT

In a pooled cohort of the two STOPDAPT-2 trials, among patients who underwent PCI, switching from dual antiplatelet therapy to clopidogrel monotherapy after 1 month reduced bleeding risk compared with 12-month DAPT. Read more

Transcatheter mitral valve replacement may benefit patients with mitral regurgitation

At 30 days, a group of 15 patients who underwent transfemoral transcatheter mitral valve replacement for moderate to severe mitral regurgitation had no deaths, strokes, reinterventions or new pacemakers, a speaker reported. Read more

SURTAVI: TAVR remains noninferior to surgery in intermediate-risk patients at 5 years

Transcatheter aortic valve replacement with a self-expanding valve was noninferior to surgical AVR in intermediate-risk patients at 5 years, according to new data from the SURTAVI trial. Read more

PCI guided by quantitative flow ratio confers better 1-year outcomes vs. standard PCI

PCI guided by quantitative flow ratio, a novel approach to estimate fractional flow reserve, was associated with lower rates of MACE at 1 year compared with PCI guided by angiography, according to results of the FAVOR III China trial. Read more

GUIDE-HF: Benefit of hemodynamic guided-management in HF similar across EF

Device therapy for pulmonary artery-pressure-guided management of patients with HF was beneficial regardless of ejection fraction, according to new data from the GUIDE-HF trial. Read more